Prostate-specific membrane antigen (PSMA)-negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. High expression of neurotensin receptor subtype 1 (NTR1) is associated with neuroendocrine differentiation of PCa, which makes NTR1 a potential target for neuroendocrine PCa. In this study, the NTR1-targeted tracer 68Ga-DOTA-NT-20.3 was synthesized, and its affinity to androgen-dependent (LNCap) and androgen-independent (PC3) xenografts was determined. Methods: 68Ga-DOTA-NT-20.3 was labeled using an automated synthesizer module, and its stability, labeling yield, and radiochemical purity were analyzed by radio-high-performance liquid chromatography. Receptor binding affinity was evaluated in NTR1-positive PC3 cells by a competitive binding assay. The biodistribution of 68Ga-DOTA-NT-20.3 in vivo was evaluated in PC3 and LNCap xenografts by small-animal PET imaging. NTR1 expression was identified by immunohistochemistry and immunofluorescence evaluation. Results: 68Ga-DOTA-NT-20.3 was synthesized successfully, with a yield of 88.07% ± 1.26%, radiochemical purity of at least 99%, and favorable stability. The NTR1 affinity (half-maximal inhibitory concentration) for 68Ga-DOTA-NT-20.3 was 7.59 ± 0.41 nM. Small-animal PET/CT of PC3 xenograft animals showed high-contrast images with intense tumor uptake, which revealed specific NTR1 expression. The tumors showed significant radioactivity (4.95 ± 0.67 percentage injected dose per gram of tissue [%ID/g]) at 1 h, which fell to 1.95 ± 0.17 %ID/g (P < 0.01, t = 8.72) after specific blockage by neurotensin. LNCap xenografts had no significant accumulation (0.81 ± 0.06 %ID/g) of 68Ga-DOTA-NT-20.3 at 1 h. In contrast, 68Ga-PSMA-11 was concentrated mainly in LNCap xenografts (8.60 ± 2.11 %ID/g), with no significant uptake in PC3 tumors (0.53 ± 0.05 %ID/g), consistent with the in vitro immunohistochemistry findings. Biodistribution evaluation showed rapid clearance from the blood and main organs (brain, heart, lung, liver, muscle, and bone), with significantly high tumor-to-liver (4.41 ± 0.73) and tumor-to-muscle (12.34 ± 1.32) ratios at 60 min after injection. Conclusion: 68Ga-DOTA-NT-20.3 can be efficiently prepared with a high yield and high radiochemical purity. Its favorable biodistribution and prominent NTR1 affinity make 68Ga-DOTA-NT-20.3 a potential radiopharmaceutical for the detection of PSMA-negative PCa and identification of neuroendocrine differentiation.

Department of Nuclear Medicine Faculty of Medicine and Dentistry Palacký University Olomouc Olomouc Czech Republic; and

Department of Nuclear Medicine Nanjing 1st Hospital Nanjing Medical University Nanjing China

Department of Nuclear Medicine Nanjing 1st Hospital Nanjing Medical University Nanjing China;

Department of Urology Drum Tower Hospital Medical School of Nanjing University Nanjing University Nanjing China

Nuclear Medicine Research Department IASON Graz Austria;

See more in PubMed

Li X, Zeng XY. Advances in epidemiology of prostate cancer in China. Cancer Res Prev Treatment. 2021;48:98–101.

Loeb S. Guideline of guidelines: prostate cancer screening. BJU Int. 2014;114:323–325. PubMed

Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951–1960. PubMed

Thompson IM, Pauler DK, Goodman PJ, et al. . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246. PubMed

Rowe SP, Johnson GB, Pomper MG, et al. . Recent updates and developments in PET imaging of prostate cancer. Abdom Radiol (NY). 2020;45:4063–4072. PubMed

Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Q J Nucl Med Mol Imaging. 2017;61:168–180. PubMed

Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23:15. PubMed PMC

Hsu EC, Rice MA, Bermudez A, et al. . Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci USA. 2020;117:2032–2042. PubMed PMC

Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383–3390. PubMed

Zhu S, Tian H, Niu X, et al. . Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene. 2019;38:4875–4884. PubMed PMC

Nikolaou S, Qiu S, Fiorentino F, et al. . The role of neurotensin and its receptors in non-gastrointestinal cancers: a review. Cell Commun Signal. 2020;18:68. PubMed PMC

Christou N, Blondy S, David V, et al. . Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death Dis. 2020;11:1027. PubMed PMC

Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Regul Pept. 2000;93:125–136. PubMed

Huang J, Wu CY, diSant’Agnese PA, Yao JL, Cheng L, Na YQ. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol. 2007;29:128–138. PubMed

Hashimoto K, Kyoda Y, Tanaka T, et al. . The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells. Lab Invest. 2015;95:283–295. PubMed

He T, Wang M, Wang H, et al. . Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. Eur J Nucl Med Mol Imaging. 2019;46:2199–2207. PubMed

Maschauer S, Prante O. Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors. J Labelled Comp Radiopharm. 2018;61:309–325. PubMed

Teodoro R, Faintuch BL, Fernández Núñez EG, Guimarães Queiróz R. Neurotensin (8-13) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol. 2011;38:113–120. PubMed

Wu Z, Li L, Liu S, et al. . Facile preparation of a thiol-reactive 18F-labeling agent and synthesis of 18F-DEG-VS-NT for PET imaging of a neurotensin receptor–positive tumor. J Nucl Med. 2014;55:1178–1184. PubMed

Deng H, Wang H, Wang MZ, Li ZB, Wu ZH. Synthesis and evaluation of 64Cu-DOTA-NT-Cy5.5 as a dual-modality PET/fluorescence probe to image neurotensin receptor-positive tumor. Mol Pharm. 2015;12:3054–3061. PubMed PMC

Alshoukr F, Prignon A, Brans L, et al. . Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011;22:1374–1385. PubMed

Prignon A, Provost C, Alshoukr F, et al. . Preclinical evaluation of 68Ga-DOTA-NT-20.3: a promising PET imaging probe to discriminate human pancreatic ductal adenocarcinoma from pancreatitis. Mol Pharm. 2019;16:2776–2784. PubMed

Zhang LL, Li WC, Xu Z, et al. . 68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging. 2021;48:483–492. PubMed PMC

Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012;39:453–464. PubMed

de Bono JS, Logothetis CJ, Molina A, et al. . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. PubMed PMC

Beer TM, Armstrong AJ, Rathkopf DE, et al. . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433. PubMed PMC